Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100 India
T 91 80 2808 2808
F 91 80 2852 3423

www.biocon.com

Ref: Bio/Acts/ CS/ SE/ Ltrs- NSE/154
October 31, 2012

The National Stock Exchange of India Limited
Exchange Plaza,
Bandra – Kurla Complex,
Bandra (East),
Mumbai- 400 051

"By Fax, Courier & Email"

Kind Attn: Mr. Hari K.

Dear Sir,

Subject: Intimation of Press Release

Please find enclosed two press releases by the Company:

1. "GE Capital to invest in Syngene, Biocon's Research Services Subsidiary"
2. "Biocon Announces Positive Results from its Global Phase 3 study with Recombinant Human Insulin"

Kindly take this intimation on record.

Thanking you,
Yours faithfully,
For Biocon Limited,

Kiran Kumar G
Company Secretary
E: Kiran.Kumar@biocon.com
M: +91 9945315151
T: +91 80 2808 2037

By "Courier"
By Fax To NSE: 022 – 2659 8237 / 38
By email: cmlist@nse.co.in

Encl. No of sheets: 3 + 3 + 1 [Cover Sheet].

Biocon Syngene

Press Release

GE Capital to invest in Syngene, Biocon's Research Services Subsidiary

Bangalore, India: October 31, 2012

Biocon, Asia's premier biotechnology Company, announced today that it has signed an agreement with GE Equity International Mauritius, a subsidiary of GE Capital Corporation ("GE Capital"), which will make a primary equity investment in its research services subsidiary, Syngene International Limited (Syngene).

As per the terms of the agreement, GE Capital would invest Rs. 125 Crores for a 7.69% equity share in Syngene. The transaction is subject to standard condition precedents including regulatory approvals.

Commenting on this development, Ms. Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon said, "GE Capital's investment in Syngene, Biocon's subsidiary, is a validation of our research services business model which has delivered consistent value to our partners as well as other stakeholders. This takes us closer to our commitment of taking Syngene through an IPO at the most opportune time."

"Welcoming the private equity investment into Syngene, **Mr Peter Bains, Director, Syngene said,** "This investment will enable Syngene to expand its integrated discovery and development services platform and harness the global outsourcing opportunity to foster high value strategic partnerships with leading pharma and biotech companies. Besides fueling our future growth, this investment also endorses the quality of innovation at Syngene and the role played by its scientific team in accelerating innovation and productivity of its global customers."

Syngene registered nearly Rs 400 Crores in FY 12. During H1, FY13, the business continues to gain momentum with sales of nearly Rs 250 Crores.

The Biocon Group was advised by Allegro Corporate Finance Advisors and Mundkur Law Partners.

About GE Capital

GE Capital offers consumers and businesses around the globe an array of financial products and services. For more information, visit www.gecapital.com or follow company news via Twitter (@GECapital)

About Syngene International Limited

Syngene is India's leading contract research organization offering integrated drug discovery and development services with capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process Research and Development, and formulation development for small and large molecules. Syngene has an expert team of over 1,500 scientists and 1 million sq. ft. of built-up laboratories equipped with state-of-the-art infrastructure to support the Research and Development programs of global pharma, biotech and nutrition companies. More information is available at www.syngeneintl.com

About Biocon Limited

Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's premier biotechnology company with a strategic focus on biopharmaceuticals and research services. Established in 1978 by Dr. Kiran Mazumdar-Shaw, the Group is an integrated, innovation-driven healthcare enterprise with offerings that traverse the entire drug development value chain. Balancing its novel molecule research pipeline with a diversified product portfolio, Biocon delivers affordable solutions to partners and customers in over 75 countries across the globe. Many of these products have USFDA and EMA acceptance. Stellar products from Biocon's stable include the world's first Pichia-based recombinant human Insulin, INSUGEN® and glargine, BASALOG® coupled with a state of the art insulin pen device, INSUPen® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®. With a team of over 6500 employees, Biocon has been recognized amongst the 'Top 20' Global Employers in biopharma sector. www.biocon.com

For Further information:

Biocon
Media Contact:
Corporate Communications

Seema Ahuja
T: +91-80-2808-2222, M:+919972317792
Email:seema.ahuja@biocon.com

Investor Contact

Sweta Pachlangiya
+91 80 2808 2045; M: +91 9686509372
Email:sweta.pachlangiya@biocon.com

Varija Belliappa
T: +91 80 2808 2223 M:+919880133507
Email: varija.belliappa@biocon.com

GE Capital
Gayatri Rath
GE Capital Communications
T: +91 124 4808918, M: +91 9873691843;
Email: gayatri.rath@ge.com

Press Release

Biocon Announces Positive Results from its Global Phase 3 study with Recombinant Human Insulin

Study demonstrates comparable safety and efficacy with the innovator product

Bangalore, India: October 31, 2012

Biocon, Asia's premier biotechnology Company, announced today that the Global Phase 3 study for its Recombinant Human Insulin (INSUGEN®), in Type 1 diabetes mellitus (T1DM) patients, demonstrates comparable safety and efficacy with the innovator product.

This multi-center, randomized study was conducted in nearly 300, T1DM patients, to compare efficacy, safety and immunogenicity of Biocon's Regular human Insulin (Insugen R®) and Isophane human Insulin (Insugen N®) against the innovator products (Actrapid® and Insulatard®) sourced from Europe. The trial met its efficacy end-point by demonstrating non-inferiority in HbA1c endpoint at 6 months. Immunogenicity and safety as evaluated by hypoglycemic events at the 6 month time point were also similar.

The Part 2 of the study to demonstrate additional safety and immunogenicity over one year is ongoing and is expected to be completed by next year with the final results expected in H1, FY14.

Data from this ongoing study along with extensive physico-chemical & biological characterization and PK-PD (pharmacokinetic & pharmaco-dynamic) data generated to date comparing Insugen-R® & Insugen-N® with the innovator products will enable Biocon to submit a robust dossier for marketing authorization in EU and other global markets.

Commenting on these results, **Ms. Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon** said, *"The positive outcome of this global phase 3 study is a significant milestone in our global insulins development program and will enable regulatory approvals of our recombinant human insulin products across developed and emerging markets. Human insulin is a widely accepted component of insulin therapy for diabetes patients and Biocon's human insulin, will present an affordable alternative to the patients worldwide. These data along with the recent PK-PD data for our insulin glargine (BASALOG®) demonstrate our commitment to pursue our global insulins strategy and deliver affordable therapy to the patients."*

"This data along with extensive characterization and PK-PD data generated to date with Biocon's regular and isophane insulin demonstrate comparability with the innovator products", said **Dr. Abhijit Barve, President R&D of Biocon.** *"This was our first global study for rh-Insulin and we are pleased with the outcome. These data and our recent positive PK-PD data for Biosimilar Glargine enable us to pursue our global development strategy for Biosimilar Insulins."*

About Human Recombinant Insulins

Insugen R® is short-acting human insulin and offers post meal control of glucose while Insugen N® is long-acting human insulin and offers basal control of glucose levels. Human recombinant insulin is used as a basal-bolus regimen or pump regimen and is most widely used by Type 1 and Type 2 diabetics in most parts of the world. Biocon's INSUGEN® is currently marketed in various countries and these data will reinforce the confidence of physicians & diabetes care providers in INSUGEN® & other products in the insulin portfolio.

Actrapid® and Insulatard® are registered brands of Novo Nordisk

About Biocon Limited

Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's premier biotechnology company with a strategic focus on biopharmaceuticals and research services. Established in 1978 by Dr. Kiran Mazumdar-Shaw, the Group is an integrated, innovation-driven

healthcare enterprise with offerings that traverse the entire drug development value chain. Balancing its novel molecule research pipeline with a diversified product portfolio, Biocon delivers affordable solutions to partners and customers in over 75 countries across the globe. Many of these products have USFDA and EMA acceptance. Stellar products from Biocon's stable include the world's first Pichia-based recombinant human Insulin, INSUGEN® and glargine, BASALOG® coupled with a state of the art insulin pen device, INSUPen® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®. With a team of over 6500 employees, Biocon has been recognized amongst the 'Top 20' Global Employers in biopharma sector. www.biocon.com

For Further information:

Media Contact:

Seema Ahuja
T: +91-80-2808-2222, M:+919972317792
Email:seema.ahuja@biocon.com

Varija Belliappa
T: +91 80 2808 2223 M:+919880133507
Email: varija.belliappa@biocon.com

Investor Contact

Sweta Pachlangiya
+91 80 2808 2045; M: +91 9686509372
Email:sweta.pachlangiya@biocon.com